Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Athersys Inc (ATHX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 197,027
  • Shares Outstanding, K 141,746
  • Annual Sales, $ 3,710 K
  • Annual Income, $ -32,240 K
  • 36-Month Beta 0.03
  • Price/Sales 7.60
  • Price/Cash Flow N/A
  • Price/Book 3.88

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.09
  • Number of Estimates 1
  • High Estimate -0.09
  • Low Estimate -0.09
  • Prior Year -0.11
  • Growth Rate Est. (year over year) +18.18%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.36 +19.12%
on 12/24/18
1.65 -1.82%
on 01/08/19
+0.18 (+12.50%)
since 12/21/18
3-Month
1.36 +19.12%
on 12/24/18
2.15 -24.65%
on 12/12/18
-0.35 (-17.77%)
since 10/23/18
52-Week
1.29 +25.58%
on 03/02/18
3.09 -47.57%
on 06/07/18
-0.32 (-16.49%)
since 01/23/18

Most Recent Stories

More News
Athersys Announces Positive Results From Its Exploratory Clinical Study of MultiStem(R) Cell Therapy for Treatment of Acute Respiratory Distress Syndrome (ARDS)

Athersys, Inc. (NASDAQ: ATHX) announced today summary results from its exploratory clinical study of the intravenous administration of MultiStem(R) cell therapy to treat patients who are suffering from...

ATHX : 1.62 (+16.55%)
Healios Agrees to Make Payment to Extend Exclusive Period for Negotiating an Option for a License to Multistem(R) Therapy for Indications in China

Athersys, Inc. (NASDAQ: ATHX) announced today the extension of HEALIOS K.K.'s (Healios) exclusive period to negotiate an option that would allow Healios to obtain a license for the development and commercialization...

ATHX : 1.62 (+16.55%)
Athersys Reports Third Quarter 2018 Results

Management to host conference call at 4:30pm EST today

ATHX : 1.62 (+16.55%)
Market Trends Toward New Normal in Crown, Athersys, CSX, Magellan Health, Spectrum Brands, and MGIC Investment -- Emerging Consolidated Expectations, Analyst Ratings

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Crown Holdings, Inc. (NYSE:CCK),...

MTG : 11.64 (-1.02%)
SPB : 53.35 (-3.39%)
MGLN : 61.25 (-1.75%)
CSX : 65.98 (+0.23%)
CCK : 48.15 (+0.67%)
ATHX : 1.62 (+16.55%)
Athersys to Host Third Quarter Financial Results Call

Athersys, Inc. (NASDAQ: ATHX) will release its third quarter 2018 financial results at approximately 4:00 p.m. Eastern Time on Tuesday, November 6th, 2018, and will host a conference call shortly thereafter...

ATHX : 1.62 (+16.55%)
Audentes Therapeutics (BOLD) Catches Eye: Stock Jumps 7%

Audentes Therapeutics (BOLD) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

BOLD : 23.96 (-2.44%)
ATHX : 1.62 (+16.55%)
Increasing Number of Cancer Cases to Fuel the Global Cancer Immunotherapy Market Growth

According to data compiled by Transparency Market Research, the global cancer immunotherapy market is expected to grow from USD 37.50 Billion in 2015 to USD 124.88 Billion by 2024 while registering a CAGR...

RGBP : 0.0022 (+10.00%)
CRIS : 1.07 (-7.76%)
BPTH : 1.96 (+8.29%)
ATHX : 1.62 (+16.55%)
BLRX : 0.60 (+3.45%)
Alnylam Files Clinical Trial Application for ALN-AAT02 in UK

Alnylam Pharmaceuticals (ALNY) submits a Clinical Trial Authorization application in the U.K. to start a phase I/II study on its early stage candidate, ALN-AAT02, for treating alpha-1 liver disease.

LGND : 112.91 (-4.23%)
CLBS : 4.71 (-5.80%)
ALNY : 80.66 (-2.96%)
ATHX : 1.62 (+16.55%)
Amgen Gets FDA Nod for Once-Weekly Regimen of Kyprolis Combo

Amgen (AMGN) gains an FDA approval for its sNDA with respect to a once-weekly dosing option of its multiple myeloma drug Kyprolis (70 mg/m2) combined with dexamethasone (Kd).

LGND : 112.91 (-4.23%)
CELG : 85.84 (-0.19%)
ATHX : 1.62 (+16.55%)
AMGN : 201.98 (-0.93%)
Medicines Company to Continue Inclisiran Studies as Planned

The Medicines Company (MDCO) gets Independent Data Monitoring Committee's recommendation to continue late-stage inclisiran studies as planned and designed.

LGND : 112.91 (-4.23%)
MDCO : 19.71 (-1.45%)
ALNY : 80.66 (-2.96%)
ATHX : 1.62 (+16.55%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade ATHX with:

Business Summary

Athersys, Inc., a late stage biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused primarily on treating critical care indications neurological conditions, cardiovascular diseases, inflammatory and...

See More

Key Turning Points

2nd Resistance Point 1.54
1st Resistance Point 1.47
Last Price 1.62
1st Support Level 1.35
2nd Support Level 1.30

See More

52-Week High 3.09
Fibonacci 61.8% 2.40
Fibonacci 50% 2.19
Fibonacci 38.2% 1.98
Last Price 1.62
52-Week Low 1.29

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar